By analyzing several publicly available gene expression datasets, we found that the overall, relapse‐free, post‐progression, distant metastasis‐free, and disease‐specific survival (OS, RFS, PPS, DMFS, and DS) outcomes for breast cancer patients exhibiting lower levels of TRIM4 expression were significantly worse than those for patients expressing higher levels of this gene in the overall breast cancer patient population (Figure 1E–H and Figure S1B,C, Supporting Information). This evidence concerns the gene TRIM4 and breast carcinoma.